Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Elicio Therapeutics (ELTX) Leases (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Leases readings, the most recent being $6.6 million for Q4 2023.

  • On a quarterly basis, Leases fell 10.71% to $6.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $6.6 million, a 10.71% decrease, with the full-year FY2023 number at $6.6 million, down 10.71% from a year prior.
  • Leases hit $6.6 million in Q4 2023 for Elicio Therapeutics, down from $6.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $7.4 million in Q4 2022 to a low of $126000.0 in Q1 2023.
  • Median Leases over the past 4 years was $4.2 million (2021), compared with a mean of $4.6 million.
  • The widest YoY moves for Leases: up 100.06% in 2023, down 96.68% in 2023.
  • Elicio Therapeutics' Leases stood at $4.1 million in 2020, then fell by 2.11% to $4.0 million in 2021, then soared by 84.4% to $7.4 million in 2022, then dropped by 10.71% to $6.6 million in 2023.
  • The last three reported values for Leases were $6.6 million (Q4 2023), $6.8 million (Q3 2023), and $7.0 million (Q2 2023) per Business Quant data.